Since the opening of the medical cannabis experiment in France in March 2021, the first results are promising. Indeed, according to a survey conducted among patients who participated in this experimentation, 91% of them are satisfied with the results obtained.

The survey was conducted among 772 patients who participated in the medical cannabis experiment. The results were published in the Journal of Pain Research. According to the survey, medical cannabis significantly reduced chronic pain, anxiety, insomnia and other symptoms related to chronic diseases.

The medical cannabis trial, launched in France in March 2021, is due to last two years. It allows doctors to prescribe cannabis to patients suffering from chronic pain or chronic diseases, such as multiple sclerosis, cancer or HIV.

The results of this survey confirm the value of medical cannabis in the treatment of chronic pain and other symptoms related to chronic diseases. However, it is important to stress that medical cannabis must be used under the supervision of a physician and its use must be subject to strict regulations.

Medical cannabis is legal in many countries, but its use remains controversial in France. The medical cannabis trial is therefore an important step in the study of the efficacy and safety of medical cannabis for patients suffering from chronic pain and chronic diseases. The results of this survey are therefore good news for patients suffering from chronic pain and seeking an alternative therapeutic solution.